Clinical Trial Update: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) [Phase 2]

View source ↗

Summary

A Phase 2 open-label study of NNZ-2591 for Prader-Willi Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• NNZ-2591 (NNZ-2591)

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Prader-Willi Syndrome | Phase 2 | Status: WITHDRAWN